GlassScriptPhysician profile
Puneet Braich
NPI 1184908691
$73,864.69
in general payments reported to CMS, 2019-2025
24 companies · $6,192 in 2025
The $6,192 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.76 · 2021: $571 · 2022: $2,157 · 2023: $35K · 2024: $30K · 2025: $6,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $9,650 · Travel and Lodging: $6,434 · Food and Beverage: $4,065 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $30,987.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,975.00 |
| Consulting Fee | $9,650.00 |
| Travel and Lodging | $6,434.47 |
| Food and Beverage | $4,065.07 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $34,444.74 | 2022-2023 | Tepezza, Uplizna |
| Amgen INC. | $30,847.73 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $5,369.58 | 2021-2024 | Centurion, Acrysof Ultrasert, Hydrus Microstent |
| Carl Zeiss Meditec USA, INC. | $1,089.33 | 2022 | |
| Abbvie INC. | $408.94 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Regeneron Healthcare Solutions, INC. | $265.02 | 2022-2024 | Eylea Hd, Eylea |
| Ivantis, INC | $238.07 | 2021 | |
| Sun Pharmaceutical Industries INC. | $207.57 | 2022-2025 | Cequa, Xelpros |
| Johnson & Johnson Surgical Vision, INC. | $193.77 | 2022-2025 | Tecnis Iol, Tecnis Simplicity |
| Alimera Sciences, INC. | $150.35 | 2022-2023 | Iluvien |
| Allergan, INC. | $90.16 | 2021-2022 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $82.59 | 2024-2025 | |
| Dompe US, INC. | $79.63 | 2021-2022 | |
| Rxsight INC | $65.16 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $64.48 | 2024 | Xdemvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $62.28 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $40.47 | 2023-2025 | Vyzulta |
| Oyster Point Pharma, INC. | $40.22 | 2023-2024 | Tyrvaya |
| Harrow Eye, LLC | $22.95 | 2025 | Vevye |
| Sight Sciences, INC. | $22.86 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.10 | 2021 | |
| Ani Pharmaceuticals, INC. | $21.52 | 2024 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $18.28 | 2021 | |
| Rayner Intraocular Lenses Limited | $16.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Braich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.